Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Authors not listed
Vanderbilt University Medical Center · 2022
Abstract
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early AD pathology. While current studies point to this biomarker as having great clinical utility, one necessary step before clinical implementation is developing safe and effective methods for disclosure of results. Past risk disclosure studies have shown that disclosing risk for AD based on genetics or amyloid status is safe, but these studies have largely focused on cognitively unimpaired individuals. This study seeks to develop comprehensible educational materials to aid risk disclosure and examine the effect of risk disclosure based on plasma p-tau181 results in a group of participants with mild cognitive impairment (MCI) at imminent risk of converting to dementia. First, educational materials will be developed in collaboration with health communication experts and then refined in focus groups made up of individuals with MCI. Educational materials will be analyzed on several key reading and comprehensibility metrics and will include personalized risk estimate based on a well-accepted risk algorithm (Cullen, et al., 2021). Next, these educational materials will be utilized to disclose risk in a randomized controlled trial with an active control arm receiving disclosure based on age, sex, and cognitive status (based on Mini-Mental State Examination), meant to mimic common methods of clinical diagnostic and prognostic decision making, and an intervention arm receiving disclosure based on the above factors plus plasma p-tau181 results. Outcomes will include measures of comprehension and psychological well-being (anxiety, depression, hopelessness, and distress) and will be assessed immediately after risk disclosure and again at six-month follow-up. It is hypothesized that risk disclosure based on plasma p-tau181 is not more psychologically harmful or less comprehensible than disclosure based on demographic factors and MMSE. This pilot study will provide a necessary step towards moving plasma p-tau biomarkers towards safe clinical implementation and will develop educational materials that can be utilized in future studies and clinical practice.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2022). Disclosing Dementia Risk Based on Plasma Phosphorylated Tau. <em>Vanderbilt University Medical Center</em>. https://clinicaltrials.gov/study/NCT05377060
Vancouver
Anonymous. Disclosing Dementia Risk Based on Plasma Phosphorylated Tau. Vanderbilt University Medical Center. 2022.
BibTeX
@misc{anon2022Disclo,
title = {Disclosing Dementia Risk Based on Plasma Phosphorylated Tau},
author = {Anonymous},
journal = {Vanderbilt University Medical Center},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Internal Medicine 2018
Open access · OA
Biomarkers for Alzheimer's disease: current status and prospects for the future
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation 2018
Open access · US-GOV
BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure
Current Alzheimer Research 2019
Citation only
Biomarkers for Alzheimer’s Disease
Altoida 2024
Open access · US-GOV
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
Journal of Alzheimer's disease : JAD 2026
Open access · OA
Exploring the interplay between frailty, Alzheimer's disease biomarkers, and cognitive functioning in patients with mild cognitive impairment: A cross-sectional study.
University of Michigan 2021
Open access · US-GOV